EQS: latest releases

News releases provided by EQS Group AG EQS Group AG.

DGAP-News: The Social Chain AG: SOCIAL Chain AG acquires 100 percent of DS Group: Revenue forecast raised to EUR 620 million in 2021

Acquisition, Commerce, Frankfurt Stock Exchange, Digital, CFO, EBITDA, Schleswig-Holstein, Teleshopping, EUR, CPO, Pleasure, ISIN, Supervisory board, Shark Tank, Dragons' Den, Growth, Dharampal Satyapal Group, Social commerce, Saskatchewan River Sturgeon Management Board, Social media, Fitness, DIY, Asgaard – German Security Group, VOX, WKN, Mecklenburg-Vorpommern, Contract, Sale, Prime Standard, Time, XETRA, DS, CEO, Knowledge, Social, Negotiation, Annual general meeting, Marketing, Annual, Retail, Online shopping
Tuesday, October 19, 2021 - 9:02am

The Social Chain AG: SOCIAL Chain AG acquires 100 percent of DS Group: Revenue forecast raised to EUR 620 million in 2021

Key Points: 
  • The Social Chain AG: SOCIAL Chain AG acquires 100 percent of DS Group: Revenue forecast raised to EUR 620 million in 2021
    The issuer is solely responsible for the content of this announcement.
  • Social Chain AG will pay a total purchase price of EUR 250.5m, which is made up of a cash component and a share component.
  • As a result of this capital increase through contributions in kind, the number of Social Chain AG shares issued will increase from 11.453 million to 14.308 million.
  • With the acquisition of DS Group, Social Chain AG expects total revenues of EUR 620m for the 2021 financial year (proforma consolidated).

EQS-News: u-blox AG: u-blox announces ultra-compact, feature-rich Bluetooth low energy SiP for industrial and indoor positioning applications

Temperature, Twitter, LinkedIn, Communication, Architecture, OTC, Internet, YouTube, SIP, Bluetooth, TAG Mobile, Engineering, Hospital, City, Traction, Solution, API, CPU, Satellite navigation device, Mobile phone
Tuesday, October 19, 2021 - 9:02am

ANNA-B4 targets applications in harsh environments such as smart lighting networks and industrial circuit breakers as well as indoor positioning use cases in manufacturing sites, warehouses, hospitals, and smart cities.

Key Points: 
  • ANNA-B4 targets applications in harsh environments such as smart lighting networks and industrial circuit breakers as well as indoor positioning use cases in manufacturing sites, warehouses, hospitals, and smart cities.
  • The SiP supports Bluetooth mesh, long range, and direction finding, Thread and Zigbee, operation up to 105 C, and is globally certified.
  • The first, ANNA-B412 , is delivered with the easy-to-use u-connectXpress command API based on industry-standard AT commands for accelerated time to market.
  • In addition to enabling concurrent communication over multiple wireless protocols, the module lets product developers build solutions using Bluetooth low energy, Zigbee, or Thread using one single module.

DGAP-News: NEW SWAB TAKES AWAY CHILDREN'S FEAR OF SWABBING

ASX, School, Child, COVID-19, Hospital, PCR, Fear, RNO, Royal Children's Hospital, Radboud University Medical Center, Degenerative disease, Anxiety, FDA, Parent, Royal Children, RCH, Vaccine, Toy
Tuesday, October 19, 2021 - 8:02am

It works with existing PCR and antigen tests and is equivalent in cost to US and European swabs.

Key Points: 
  • It works with existing PCR and antigen tests and is equivalent in cost to US and European swabs.
  • Rhinomed CEO Michael Johnson commented,
    "Testing rates in children remain low due in part to the anxiety and distress children can experience when being tested with a standard swab.
  • We have sought to develop a swab that not only works better, but is easy and even fun to use - not just for the children but their parents and healthcare workers.
  • Rhinoswab JuniorTM will make repeat rapid antigen testing at schools, homes and other venues easier and more comfortable for children."

Pharnext strengthens its management team with three key appointments to support ongoing development of PXT3003 toward approval and commercialization

ISIN, Gastroenterology, Patient, Senior Consultant, Pharmaceutics, Neurodegeneration, URD, The Company, IIT BHU, Alexion Pharmaceuticals, Neurology, Drug discovery, Intelligence, Xavier University, Intention, Charcot–Marie–Tooth disease, AMF, Tablet, Mission statement, Artificial intelligence, Abhijit, CMC, HEC Paris, General manager, Genetics, Marketing, Regulatory News Service, Growth, RAC, Alzheimer's disease, Genomics, Certification, Master, Prospectus, Trial of the century, GlaxoSmithKline, Regulatory affairs, Raj Thota, CET, Villanova University, Degenerative disease, COO, IIT, Therapy, Company, Security (finance), Pharmaceutical industry
Tuesday, October 19, 2021 - 8:01am

in Pharmaceutical Technology from IIT BHU, India, and M.B.A. in general management from Xavier University USA.

Key Points: 
  • in Pharmaceutical Technology from IIT BHU, India, and M.B.A. in general management from Xavier University USA.
  • He also completed a Regulatory Affairs Certification (RAC) from Regulatory Affairs Professional Society and Lean Six Sigma Greenbelt Certification from Villanova University, USA.
  • Raj's extensive experience in pharmaceutical development and Abhijit's past work in navigating drug development with global regulatory authorities will considerably augment the strength of our senior management team.
  • Our pivotal Phase III clinical study of PXT3003 in CMT1A, the PREMIER trial, is currently ongoing in the US and Europe and remains our key focus."

EQS-News: Cosmiq Universe AG: LIGHT ART EXPEDITION ARCTICA 'Love your Planet'

Universe, Freezing, Rainforest, Love, Exploration, Intention, Awareness, Light, Social media, Weather, Artificial intelligence, Instagram, Blockchain, NFT, Human rights, Nature, COVID19, Beauty, Hope, UN, Snow, CO2, Heart, Arctic Ocean, Music, International Commission of Jurists, Film
Tuesday, October 19, 2021 - 8:01am

The Light Art Expedition Arctica "Love your Planet" has been successfully completed.

Key Points: 
  • The Light Art Expedition Arctica "Love your Planet" has been successfully completed.
  • Zug, October 19, 2021 - The light art expedition to the Arctic took place under weather extreme conditions.
  • One of Gerry Hofstetter's key focus points was to raise awareness for the interconnectedness and fragility of the Arctic, Antarctic and the rainforest.
  • Her global movement and values connect all the hearts of the world for a more loving and sustainable planet Earth.

Epazz, Inc.: Epazz's CryObo Technology to Digitalize Harvests for Ireland Farmers Using Blockchain and Drone Technology

Bitcoin, The O.C. (season 3), Josh Passley, OTC Markets Group, Technology, Harbor, Private Securities Litigation Reform Act, Income, Intention, Growth, White label, Farmer, Terminology, Mission statement, CEO, Blockchain, Review, Forward-looking statement, Public sector, Government, Cryptocurrency
Tuesday, October 19, 2021 - 8:01am

CryObo technology will focus on the real estate market, which includes farmland.

Key Points: 
  • CryObo technology will focus on the real estate market, which includes farmland.
  • Real estate developers will appraise for current value; however, the future of real estate will be evaluated.
  • The goal is for real estate developers to assess the future value of properties once land is developed and buildings are constructed.
  • CryObo Inc. will enhance its software to give early-access companies backed by real assets an easy way to access the token markets.

DGAP-News: Advanced Blockchain AG Has Invested in Obol Technologies

Ethereum, Secret sharing, Technology, ISIN, Acrylic, News, DGAP, XETRA, Obol, SSV, Security (finance), Cryptocurrency
Tuesday, October 19, 2021 - 8:01am

Advanced Blockchain AG (Frankfurt, Primary Market Dsseldorf, XETRA: ISIN DE000A0M93V6)participated in the Obol Technologies seed financing round with a 6-figure investment.

Key Points: 
  • Advanced Blockchain AG (Frankfurt, Primary Market Dsseldorf, XETRA: ISIN DE000A0M93V6)participated in the Obol Technologies seed financing round with a 6-figure investment.
  • The company invested alongside significant investors including Ethereal Ventures, Acrylic, Coinbase, and several top angel investors within this space.
  • Obol Technologies ( https://obol.tech/ ) is an open-source and permissionless infrastructure protocol made for staking digital assets.
  • Its mission is to serve as the primary coordination layer for trustless and configurable staking on public blockchain networks.

DGAP-News: Delivery Hero invests in on-demand grocery delivery company Gorillas to further advance the quick commerce industry

Delivery Hero, EUR, E-commerce, USD, CEO, United Kingdom, Industry, City, DST, Gesellschaft mit beschränkter Haftung, DAX, Food delivery, Retail
Tuesday, October 19, 2021 - 7:01am

Delivery Hero is taking a minority stake in the Berlin-based on-demand grocery delivery company Gorillas, investing USD 235 million (EUR 200 million)

Key Points: 
  • Delivery Hero is taking a minority stake in the Berlin-based on-demand grocery delivery company Gorillas, investing USD 235 million (EUR 200 million)
    Delivery Hero led Gorillas' series C funding round, now holding approximately 8% in the company
    Berlin, 19 October 2021 - Delivery Hero SE ("Delivery Hero"), the world's leading local delivery platform, today announced that it has invested USD 235 million (EUR 200 million) in the Berlin-based on-demand delivery startup Gorillas Technologies GmbH ("Gorillas").
  • Delivery Hero is proud to support companies that disrupt the delivery landscape through an innovative and entrepreneurial spirit.
  • Niklas stberg, CEO and Co-Founder of Delivery Hero, said: "Delivery Hero is on a mission to advance quick commerce globally and we see Gorillas as one of the leaders in Europe and the US.
  • The company started as a food delivery service in 2011 and today runs its own delivery platform on four continents.

Smiths News (SNWS) Initiation - Predictable cash flows and growing dividends

DDM, Research, Smiths News, News, DCF, COVID-19
Tuesday, October 19, 2021 - 7:01am

While the print sector is declining, revenue is predictable and management has a clearly demonstrable cost-saving track record such that cash flow is strong and profits are broadly flat, post COVID-19.

Key Points: 
  • While the print sector is declining, revenue is predictable and management has a clearly demonstrable cost-saving track record such that cash flow is strong and profits are broadly flat, post COVID-19.
  • This means that debt is being paid down and dividends are likely to become an increasing feature.
  • We value Smiths News at 77.4p/share based on a discounted cash flow (DCF) model, more than twice the current share price.
  • Given the predictable and consistent cash flow of the core business, we believe this is a reasonable methodology to adopt.

RUBIS: Share capital decrease by cancellation of own shares

Acquisition, Regulatory News Service, Share repurchase, Saskatchewan River Sturgeon Management Board, Partnership, Shareholder, Security (finance)
Tuesday, October 19, 2021 - 7:01am

The second tranche was launched on July 12, 2021 for a maximum duration of four months with a maximum amount of 60 million allocated to the acquisition of up to 1.5 million shares.

Key Points: 
  • The second tranche was launched on July 12, 2021 for a maximum duration of four months with a maximum amount of 60 million allocated to the acquisition of up to 1.5 million shares.
  • This tranche has been completed on October 4, 2021 with the acquisition of 1.5 million of shares.
  • The share capital decrease is effective as of October 19, 2021, as indicated in the Euronext notice dated on October 15, 2021.
  • Following this cancellation, the share capital amounts to 128,097,350 euros, divided into 102,477,880 shares (102,471,190 ordinary shares and 6,690 preferred shares (with no voting rights)).

Travis Perkins: Transaction in Own Shares

European Union, Article, European Union (Withdrawal) Act 2018, Treasury, London, The Company, London Stock Exchange, Retained firefighter, Common stock, Company, Security (finance)
Tuesday, October 19, 2021 - 7:01am

Dissemination of a Regulatory Announcement, transmitted by EQS Group.

Key Points: 
  • Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • Travis Perkins plc (the "Company") announces that it has purchased the following number of its ordinary shares of 11.205105 pence each on the London Stock Exchange, from Citigroup Global Markets Limited as part of its buy-back programme announced on 21 September 2021:
    Number of Ordinary Shares Purchased:
    The repurchased shares will be held in treasury (and some may subsequently be transferred to the Company's employee benefit trust).
  • Following the purchase of these shares, Travis Perkins holds 902,179 of its ordinary shares in treasury and has 224,123,747 ordinary shares in issue (excluding treasury shares).

DGAP-News: Formycon and SCG Cell Therapy Announce Collaboration and License Agreement for Formycon's COVID-19 Drug FYB207

Biotechnology, Institute, Cancer, SCG, COVID-19, Ophthalmology, Marketing, ISIN, Hepatitis B, Helicobacter pylori, Virology, Institute of technology, Coronavirus, Severe acute respiratory syndrome coronavirus 2, WKN, CEO, Patient, Human papillomavirus infection, Conditional sentence, Infection, ACE2, Pharmaceutical industry, Vaccine
Tuesday, October 19, 2021 - 6:01am

Under the terms of the agreement, SCG has access to Formycon's ACE2 fusion protein technology and has acquired an exclusive license to develop, manufacture and commercialize FYB207 in the Asia-Pacific (APAC) region (except Japan).

Key Points: 
  • Under the terms of the agreement, SCG has access to Formycon's ACE2 fusion protein technology and has acquired an exclusive license to develop, manufacture and commercialize FYB207 in the Asia-Pacific (APAC) region (except Japan).
  • The APAC region is home to about 60% of the world's population and is the world's second largest healthcare market.
  • SCG will be responsible for the development and manufacturing of FYB207 in Asia, and if approved, bring this innovative COVID-19 drug to patients and healthcare providers in the Asia-Pacific region."
  • Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of a COVID-19 drug FYB207.

DGAP-News: Pacifico Renewables Yield AG partners with project developer ACE Power and secures access to a one GW+ pipeline in Australia

Hydrogen, Acquisition, Network analyzer (AC power), Plant, Coal, G20, European Union, ISIN, News, Goal, Retirement, Financial Oversight and Management Board for Puerto Rico, Terminology, ACE, Deep Decarbonization Pathways Project, DGAP, Electricity, Entrepreneurship, Wind, United Kingdom, Industry, Forward-looking statement, Partnership, CIA, Union, Environment, Company, Security (finance), Renewable energy
Tuesday, October 19, 2021 - 5:00am

Gruenwald, October 19, 2021 - Today, Pacifico Renewables Yield AG (ISIN: DE000A2YN371) (the "Company", "Pacifico"), an independent producer of electricity from renewable sources, signed a right of first offer agreement with ACE Power Development Pty Ltd and ACE Power Operations Pty Ltd ("ACE Power"), a renewable energy project developer based in Australia.

Key Points: 
  • Gruenwald, October 19, 2021 - Today, Pacifico Renewables Yield AG (ISIN: DE000A2YN371) (the "Company", "Pacifico"), an independent producer of electricity from renewable sources, signed a right of first offer agreement with ACE Power Development Pty Ltd and ACE Power Operations Pty Ltd ("ACE Power"), a renewable energy project developer based in Australia.
  • This partnership grants Pacifico priority access to ACE Power's pipeline of currently more than one GW in Australia.
  • The current pipeline of ACE Power mainly comprises nine large-scale solar projects across Australia.
  • The partnership with ACE Power demonstrates the Company's ambitions to continue adding project developers with considerable industry experience to its platform.

DGAP-News: FIRST HYDROGEN TO BUILD TWO HYDROGEN-FUEL-CELL POWERED LIGHT COMMERCIAL DEMONSTRATOR VANS

Hydrogen, DGAP, FSE, Industry, Solution, Big data, OTC, News, AVL, Vans, United Kingdom, TSX, THIS, ADAS, FIRST, THE, Company, MAN, Motor vehicle, CO2, Natural gas, Cryptocurrency
Monday, October 18, 2021 - 9:07pm

The Company under the agreements with AVL and Ballard, announced in its press release of June 11, 2021 has started the development and build of two hydrogen fuel cell powered light commercial demonstrator vans at the AVL facilities in the United Kingdom for delivery in Q3 2022.

Key Points: 
  • The Company under the agreements with AVL and Ballard, announced in its press release of June 11, 2021 has started the development and build of two hydrogen fuel cell powered light commercial demonstrator vans at the AVL facilities in the United Kingdom for delivery in Q3 2022.
  • The Company recently changed its name to First Hydrogen to better reflect the business of the company.
  • Hydrogen is a clean energy fuel, hydrogen fuel cell powered vehicle are more efficient than internal combustion engine, are carbon-free and safer than hydrocarbon fuels.
  • First Hydrogen Corp. is a Vancouver based company focused on zero-emission vehicles and supercritical carbon dioxide extractor systems.

DGAP-News: Pediatric Lyme Disease-'An Epidemic Within a Pandemic!'-to be Focus of Free Webinar Hosted by Quidel Corporation Oct. 21

Headache, Prevalence, Medical Society, Parent, Program, Blood, Lung, Nasdaq, Heart, Physician, Privacy, Population, Child, Infection, FDA, Disease, Joint, Skin, Tick-Borne Disease Alliance, Patient, Chills, Bacteria, EDT, Pediatrics, FIA, Fever, COVID-19, Vaccine
Monday, October 18, 2021 - 8:03pm

'-to be Focus of Free Webinar Hosted by Quidel Corporation Oct. 21

Key Points: 
  • '-to be Focus of Free Webinar Hosted by Quidel Corporation Oct. 21
    The issuer is solely responsible for the content of this announcement.
  • In response to this troubling fact, an important webinar focused on how Lyme disease affects the pediatric population will be held on Thursday, Oct. 21.
  • The free webinar-titled Pediatric Lyme Disease: 'An Epidemic Within a Pandemic!
  • '-is part of an ongoing series hosted by Quidel, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions.

Turkiye Garanti Bankasi A.S.: Global and Medium Term Note Program Yearly Renewal

Head Office, Book, Capital Markets Board of Turkey, Record, Board of directors, Sydney Water Head Office, Board, GMTN, USD
Monday, October 18, 2021 - 7:05pm

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • On January 14, 2021, T. Garanti Bankas A.. Board of Directors authorized the Head Office to take the necessary actions for the yearly renewal of the GMTN program.
  • The Capital Markets Board's approval was granted on February 18, 2021 and the renewal has been completed as of October 15, 2021 with a size of USD 6.000.000.000.
  • In contradiction between the Turkish and English versions of this public disclosure, the Turkish version shall prevail.

Turkiye Garanti Bankasi A.S.: Coupon payment of Bank Bonds to Qualified Investors

Book, Record, Board, Audit
Monday, October 18, 2021 - 7:05pm

In contradiction between the Turkish and English versions of this public disclosure, the Turkish version shall prevail.

Key Points: 
  • In contradiction between the Turkish and English versions of this public disclosure, the Turkish version shall prevail.
  • We declare that our above statements are in conformity with the principles included in the Board's Communiqu, Serial II Nr.15.1, that it exactly reflects the information we received; that the information complies with our records, books and documents; that we did our best to obtain the correct and complete information relative to this subject and that we are responsible for the declarations made in this regard.
  • Contact Garanti BBVA Investor Relations:

M&G Credit Income Investment Trust plc: Net Asset Value

MAR, Company, Security (finance)
Monday, October 18, 2021 - 6:06pm

M&G Credit Income Investment Trust plc: Net Asset Value

Key Points: 
  • M&G Credit Income Investment Trust plc: Net Asset Value
    Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR), transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • The Company announces that as at close of business on 30th September 2021, the unaudited cum-income net asset value per ordinary share was 102.07 pence.

DGAP-News: ABIVAX: ABX464 shows excellent long-term efficacy data in Abivax's phase 2b maintenance Trial in ulcerative colitis

EMA, Cancer, Ulcerative colitis, European Medicines Agency, ISIN, Hepatocellular carcinoma, JAK, PP, FDA, Volunteering, Patient, Abivax, UC, ITT, Twitter, Maintenance, Safety, Degenerative disease, Pharmaceutical industry, Medical device
Monday, October 18, 2021 - 5:07pm

During the induction and the maintenance phases of the phase 2b study, ABX464 continued to show a good safety and tolerability profile, confirming the data already generated in over 850 patients and volunteers treated with ABX464 so far.

Key Points: 
  • During the induction and the maintenance phases of the phase 2b study, ABX464 continued to show a good safety and tolerability profile, confirming the data already generated in over 850 patients and volunteers treated with ABX464 so far.
  • In May and September 2021, Abivax already announced the top-line and full results , respectively, of this randomized, placebo-controlled phase 2b trial of ABX464 in moderate to severe ulcerative colitis patients following induction treatment.
  • 254 patients with moderate to severe active ulcerative colitis were enrolled in this phase 2b trial and randomized to three once-daily oral ABX464 treatment groups (25mg, 50mg and 100mg) or placebo.
  • In addition to the phase 2b maintenance results, Abivax recently also reported efficacy data from its ongoing phase 2a maintenance study in UC.

Pharnext: Data from First Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A, the PLEO-CMT Trial, Published in the Orphanet Journal of Rare Diseases

Human, Schwann cell, Safety, AMF, Baclofen, Disease, FDA, Sorbitol, Lead, Phase II, Orphanet Journal of Rare Diseases, CET, Charcot–Marie–Tooth disease, Patient, Mission statement, Intention, Doctor of Philosophy, URD, ClinicalTrials.gov, Life, Neurodegeneration, HD, Company, Prospectus, MD, Genomics, Drug discovery, Degenerative disease, EMA, Occupational therapy, Genta (company), Trial of the century, ISIN, OJRD, Therapy, Intelligence, CMT, Artificial intelligence, Running, Naltrexone, PMP22, III, Walking, Wheelchair, Prevalence, LD, Alzheimer's disease, Regulatory News Service, High, ALS, Muscle atrophy, Muscle, Pharmaceutical industry, Security (finance)
Monday, October 18, 2021 - 5:07pm

Pharnext: Data from First Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A, the PLEO-CMT Trial, Published in the Orphanet Journal of Rare Diseases

Key Points: 
  • Pharnext: Data from First Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A, the PLEO-CMT Trial, Published in the Orphanet Journal of Rare Diseases
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • This extension study is still ongoing, and 130 patients are still receiving treatment with high-dose PXT3003.
  • The second international, randomized, double-blind, two-arm placebo-controlled Phase III study of PXT3003, the PREMIER trial, was initiated in March 2021 in the U.S.
  • PXT3003 has shown promising and consistent results across preclinical and clinical studies in Phase II and Phase III (PLEO-CMT and PLEO-CMT-FU).

LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children

EMA, List of life sciences, AAV, Fats, Generides, Data monitoring committee, Genome, Industry, Liver, Time, Nasdaq, Methylmalonyl-CoA, Risk, Cancer, Growth, Mouse, Lethargy, Trial of the century, Capsid, European Medicines Agency, Protein, Tissue, Saavi, Methylmalonyl-CoA mutase, Brain, Mutation, FDA, Disease, DNA, Clinical trial, Patient, Survival, Food, Methylmalonic acidemia, DSMB, Seizure, Company, CRISPR, Drug development, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Vomiting, SUNRISE, MD, Safety, Hepatocyte, Therapy, Homologous recombination, Lists of diseases, Pharmaceutical industry, Vaccine
Monday, October 18, 2021 - 5:07pm

www.arixbioscience.com

Key Points: 
  • www.arixbioscience.com
    - Based on safety data from first two patients, independent Data Safety Monitoring Board recommended continuation of trial, enabling enrollment of children as young as six months and dose escalation
    LEXINGTON, Mass., Oct. 18, 2021 -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced clinical trial results demonstrating the first-ever in vivo genome editing in children.
  • The SUNRISE trial is evaluating the safety, tolerability and preliminary efficacy of LB-001, the company's investigational, single-administration genome editing therapy, in pediatric patients with methylmalonic acidemia (MMA).
  • These results follow a recommendation from the independent Data Safety Monitoring Board (DSMB) overseeing the SUNRISE trial to continue the study without modification.
  • We look forward to continuing to progress the clinical study to better understand the biochemical and clinical effect of this genome editing therapy."

DGAP-News: Newron Receives Fifth Tranche from Financing Agreement with European Investment Bank (EIB)

Central nervous system, DGAP, European Investment Bank, EFSI, News, EIB, European Fund for the Balkans, Schizophrenia, Patient, European Union, CEST, Company, Investment, CEO, United Arab Emirates, Peripheral nervous system, Parkinson's disease, EUR, XETRA, Tranche, Security (finance), Pharmaceutical industry
Monday, October 18, 2021 - 5:07pm

The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment plan for Europe.

Key Points: 
  • The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment plan for Europe.
  • Tranche 5 consists of EUR 7.5 million and will primarily be used to support the Company's development programs in diseases of the central nervous system.
  • The first four tranches of the loan, totaling EUR 32.5 million, were received by Newron in 2019, 2020 and in September 2021.
  • Newron is developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

EQS-News: Key Figures 15.10.2021

Risk, News, HBM, Income, Mail
Monday, October 18, 2021 - 5:07pm

Wenn Sie keine Mitteilungen von HBM Healthcare Investments mehr wnschen, knnen Sie diese hier a bbestellen .

Key Points: 
  • Wenn Sie keine Mitteilungen von HBM Healthcare Investments mehr wnschen, knnen Sie diese hier a bbestellen .
  • Should you wish to unsubscribe from all HBM Healthcare Investments news, please unsubscribe here.
  • This message may contain confidential or privileged Information and is intended only for the use of the addressee named above.
  • Some information quoted was obtained from external sources HBM considers to be reliable.

Royal KPN N.V. Press Release: KPN reports on progress of € 200m share buyback

KPN, Share repurchase, Car rental
Monday, October 18, 2021 - 5:07pm

KPN has repurchased 6,217,238 KPN ordinary shares in the period from 11 to 15 October 2021.

Key Points: 
  • KPN has repurchased 6,217,238 KPN ordinary shares in the period from 11 to 15 October 2021.
  • The shares were repurchased at an average price of 2.69 per share for a total consideration of 16.7m.
  • These repurchases were made as part of the 200m share buyback started on 23 August 2021 with the purpose to reduce the capital of KPN.
  • The total number of ordinary shares repurchased to date is 62,072,854 for a total consideration of 169.1m.

Sistema PJSFC: Sistema reports acquisition of shares under buyback programme

London Stock Exchange, London, Moscow Exchange, Telecommunication, SSA, Agriculture, RUB, Acquisition, Sistema, Tourism, Paper, Bank
Monday, October 18, 2021 - 5:07pm

Sistema was notified of the acquisition by Sistema Finance on October 18 2021.

Key Points: 
  • Sistema was notified of the acquisition by Sistema Finance on October 18 2021.
  • Since the beginning of the Programme Sistema Finance has acquired 224 326671 ordinary shares.
  • Revenue in 2020 was RUB 691.6 billion; total assets equalled RUB 1.4 trillion as of 31 December 2020.
  • Sistema's ordinary shares are listed under the "AFKS" ticker on the Moscow Exchange.

Hardman & Co Research: City of London Investment Group (CLIG): Good performance offsets weak markets

NEWS, Financial Conduct Authority, Companies House, Directive 2014/65/EU, Research, FCA, Knowledge, Hardman & Co., Security (finance), Financial adviser
Monday, October 18, 2021 - 4:07pm

About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities.

Key Points: 
  • About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities.
  • Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.
  • Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services.
  • Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843.

DGAP-News: tokentus investment AG conducts public offering and parallel private placement after approval of the securities prospectus

Investor relations, DGAP, Frankfurt, WKN, News, ISIN, Federal republic, Federal Financial Supervisory Authority, German Federation of Consumer Organisations v Planet49 GmbH, Investment, AG, Prospectus, Sale, Person, Financial Oversight and Management Board for Puerto Rico, CET, Acquisition, Security (finance), Cryptocurrency
Monday, October 18, 2021 - 3:17pm

The approved securities prospectus can be viewed and downloaded from the website of tokentus investment AG at www.tokentus.com in the "Investor Relations" section under the menu item "Public Offering 2021".

Key Points: 
  • The approved securities prospectus can be viewed and downloaded from the website of tokentus investment AG at www.tokentus.com in the "Investor Relations" section under the menu item "Public Offering 2021".
  • Investors may submit purchase offers to tokentus investment AG within the offer period.
  • The already announced issue price per new no-par value registered share is 2.55 for both the public offering and the private placement.
  • Interested investors are solely responsible for analyzing, weighing and evaluating the potential opportunities and risks of an investment in shares of tokentus Investment AG.

SIP Purchase, PDMR Shareholding & TVR

Aquaculture, Technology, Certification, ISO 9001:2015, Company
Monday, October 18, 2021 - 3:17pm

It operates in four worldwide locations: Lancaster, Aberdeen and Ulverston in the UK and Puerto Montt in Chile.

Key Points: 
  • It operates in four worldwide locations: Lancaster, Aberdeen and Ulverston in the UK and Puerto Montt in Chile.
  • The Company's Oceansense leak detection systems have a global reputation as the industry standard solution and have been deployed successfully on hundreds of jobs.
  • OTAQ's Dragonfish laser measurement system is fast becoming recognised as one of the most accurate underwater precision laser measurement systems available.
  • The Company makes this announcement, including the notification(s) below, in accordance with the requirements of the EU Market Abuse Regulation.

PJSC RusHydro: Agenda of the Board of Directors meeting on October 29, 2021

JSC, Business, Energy and Industrial Strategy Committee, LSE, Public–Private Investment Program for Legacy Assets, Director, Compliance, Electricity, OTCQX, Company, Boguchansky, Review, Business plan, Board, Program, Group, PJSC, MAR, Animal, Manufacturing, Audit, Renewable energy
Monday, October 18, 2021 - 3:17pm

PJSC RusHydro: Agenda of the Board of Directors meeting on October 29, 2021

Key Points: 
  • PJSC RusHydro: Agenda of the Board of Directors meeting on October 29, 2021
    Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR), transmitted by EQS Group.
  • Agenda of the Board of Directors meeting on October 29, 2021
    October 18, Moscow, Russia.
  • PJSC RusHydro (ticker symbol: MOEX, LSE: HYDR; OTCQX: RSHYY) announces the agenda of the Board of Directors meeting to be held in absentia on October 29, 2021.
  • On determining the position of the Company's (Company's representatives) on the agenda of the Board of Directors of JSC FEGC.

The republication and redistribution of any and/or all of the PR Newswire Content Feed displayed on this is website is strictly prohibited.